Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Advertisement

Advertisement




Jun
20
Today In Oncology
FDA Approves Capivasertib Plus Abiraterone and Prednisone for Metastatic Prostate Cancer
AGA Recommends Colonoscopy Over Alternative Colorectal Cancer Screening Methods
AI-Assisted Tumor Volume Response Criteria Outperform Physician Assessments and RECIST Criteria in Pleural Mesothelioma
Overall Survival With EBRT in Hepatocellular Carcinoma
HCC TACE Plus STRIDE With or Without Lenvatinib
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo